<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01168414</url>
  </required_header>
  <id_info>
    <org_study_id>NMRR-10-466-5929</org_study_id>
    <nct_id>NCT01168414</nct_id>
  </id_info>
  <brief_title>A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Randomized, Comparison of the Effects of Ganfort and Duotrav on Intraocular Pressure in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Open Label/Evaluator-blind/Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Malaysia</source>
  <brief_summary>
    <textblock>
      This is a single-center, cross-over comparison parallel group randomized trial designed to
      evaluate the efficacy and safety of Ganfort compared to Duotrav for a treatment period of 8
      weeks each.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean intraocular pressure of the 12-hour IOP curve</measure>
    <time_frame>8 weeks</time_frame>
    <description>To compare the mean intraocular pressure of the 12-hour IOP curve for Ganfort and Duotrav</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean intraocular pressure</measure>
    <time_frame>12 hours</time_frame>
    <description>Difference in mean IOP for Ganfort and Duotrav</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Ocular Hypertension</condition>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Ganfort</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed combination of Bimatoprost and Timolol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duotrav</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed combination of Travoprost and Timolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganfort</intervention_name>
    <description>Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)</description>
    <arm_group_label>Ganfort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duotrav</intervention_name>
    <description>Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)</description>
    <arm_group_label>Duotrav</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Visual acuity 6/60 or better

          2. Patients who are controlled (IOP &lt; 21 mmHg) on non-fixed combination of Latanoprost &amp;
             Timolol for at least 3 months before the baseline visit and

          3. Patients on mono-therapy either Latanoprost or Timolol who are eligible for dual
             therapy being not satisfactorily controlled (IOP&gt;21mmHG)

        Exclusion Criteria:

          1. Angle closure glaucoma

          2. Neovascular Galucoma

          3. Secondary open angle glaucoma

          4. Ocular infection/inflammation within 3 months

          5. Ocular surgery within 3 months

          6. History of Refractive surgery

          7. Argon laser trabeculoplasty/Selective laser trabeculoplasty

          8. Pregnancy/nursing

          9. Hypersensitivity to benzalkonium chloride or to any other components of the trial
             drugs solution.

         10. Patients in whom beta-blockers are contraindicated

         11. Patients on any drugs known to affect IOP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ophthalmology Department, Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2010</study_first_submitted>
  <study_first_submitted_qc>July 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2010</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Lee Ming Yueh</name_title>
    <organization>Ophthalmology Department, Hospital Kuala Lumpur</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Cloprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

